PCL microparticle-dispersed PLGA solution as a potential injectable urethral bulking agent.
The PCL microparticle-dispersed PLGA solutions were prepared as a potential injectable urethral bulking agent. The mixture solutions were prepared by mixing polycarprolactone (PCL) microparticles (diameter, 100 approximately 200mum; fabricated by a temperature-induced phase transition method) and poly(dl-lactic-co-glycolic acid) (PLGA) solution (dissolved in tetraglycol to 10wt%) with different PCL microparticle to PLGA solution ratio. The mixture solution was solidified by the precipitation of PLGA when the solution was contact with water. In contact with water, the PCL microparticles exhibited a well-packed structure entrapped in a solidified porous PLGA matrix, which can effectively prevent the microparticle migration in the body and retain its initial volume even after PLGA matrix degradation. The PCL microparticle-dispersed PLGA solution (particle to solution ratio, 45/55 (w/v)) was easily injected through 18G needle into back of hairless mouse (subcutaneously) and stably located at the apply site. The surrounding tissue including blood vessel were gradually infiltrated into the implant up to 8 weeks without the initial injected volume change and with little inflammatory response. The PCL microparticle-dispersed PLGA solution may be a good candidate as an injectable bulking agent for the treatment of urinary incontinence owing to its good injectability, volume retention potential as well as biocompatibility.
Oh
Se Heang
SH
Department of Polymer Science and Engineering, Hannam University, 133 Ojeong Dong, Daedeog Gu, Daejeon 306-791, Republic of Korea.
Lee
Ji Youl
JY
Ghil
Sung Ho
SH
Lee
Sang Sup
SS
Yuk
Soon Hong
SH
Lee
Jin Ho
JH
D000818:Animals; D007279:Injections, Subcutaneous; D019344:Lactic Acid / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D051379:Mice; D008812:Mice, Hairless; D011100:Polyglycolic Acid / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D014521:Urethra / Q000187:drug effects / Q000473:pathology; D014549:Urinary Incontinence / Q000188:drug therapy*
D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid